A proof-of-concept randomized-controlled trial of omalizumab in patients with severe difficult to control nonatopic asthma Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012
Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009
Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012
Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003
Efficacy of omalizumab in patients with concomitant allergic asthma and atopic dermatitis: a pilot study Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
Omalizumab in severe allergic asthma associated with COPD: a multicentric cohort study Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021
Dupilumab efficacy in children with uncontrolled, moderate-to-severe asthma with and without an allergic phenotype Source: Virtual Congress 2021 – Advances in childhood asthma: biologics, biomarkers and infections Year: 2021
Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019
A randomized double-blind study of specific immunotherapy (SIT) in patients with seasonal allergic rhinitis: effects on clinical and inflammatory markers Source: Eur Respir J 2001; 18: Suppl. 33, 482s Year: 2001
Real-life long-term omalizumab therapy in children with severe allergic asthma Source: Eur Respir J 2015; 46: 856-859 Year: 2015
Effectiveness of omalizumab in Canadian patients with allergic asthma: A retrospective study. Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017
Cost-effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: adaptation of INNOVATE and ETOPA data to the Netherlands Source: Annual Congress 2007 - Cost-effectiveness in diagnosis, therapy and care Year: 2007
Nasal beclomethasone plus loratadine in patients with rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial Source: Eur Respir J 2007; 30: Suppl. 51, 547s Year: 2007
Follow-up of patients with moderate-severe allergic asthma treated with omalizumab Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010
Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017
Efficacy of montelukast in patients with concomitan persistent allergic rhinitis and asthma Source: Eur Respir J 2006; 28: Suppl. 50, 663s Year: 2006
APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma Source: International Congress 2015 – Immune aspects of asthma and other airway diseases Year: 2015
A population-based clinical study of allergic and non-allergic asthma Source: Annual Congress 2008 - Markers and triggers of asthma Year: 2008
A randomised controlled trial of zafirlukast in acute asthma Source: Eur Respir J 2005; 26: Suppl. 49, 254s Year: 2005